Affiliates of Kaiser Permanente have agreed to pay $556 million to resolve allegations that they improperly boosted Medicare Advantage payments over nearly a decade by submitting invalid diagnosis codes, in one of the largest False Claims Act settlements to date involving the fast‑growing program.
The settlement, announced Wednesday by the Justice Department, caps a government investigation into what prosecutors described as a years‑long, highly structured effort by Kaiser to “game the system and pad their profits” by retrospectively inflating risk scores for Medicare Advantage enrollees in California and Colorado.
Kaiser, an integrated healthcare consortium headquartered in Oakland, Calif., owns and operates Medicare Advantage Organizations that offer plans nationwide. The settling affiliates are Kaiser Foundation Health Plan Inc.; Kaiser Foundation Health Plan of Colorado; The Permanente Medical Group Inc.; Southern California Permanente Medical Group; and Colorado Permanente Medical Group P.C.
While the resolution is civil and Kaiser does not admit liability, the case sends an unmistakable signal to health insurers and risk‑bearing medical groups that the federal government is intensifying scrutiny of risk‑adjustment practices in Medicare Advantage – with direct consequences for insurers’ compliance, governance and financial exposure.
Pressure to add diagnoses
At the heart of the government’s complaint is the complex mechanism by which Medicare Advantage plans are paid. Under Medicare Part C, the Centers for Medicare & Medicaid Services (CMS) pays private plans a fixed monthly amount per enrollee, adjusted for risk based on diagnosis codes submitted by the plans. Plans receive more for beneficiaries deemed sicker and less for healthier members.
Those diagnosis codes must be supported by the medical record of a face‑to‑face visit, and in the outpatient setting must have required or affected care, treatment or management at that visit.
Prosecutors allege that from 2009 to 2018, Kaiser systematically violated those rules by mining past medical histories to identify potential diagnoses that had not been submitted to CMS, then pressuring physicians to add those diagnoses after the fact, via “addenda” to patient records, even when they had not been considered or addressed in the visits in question.
The government says Kaiser developed mechanisms to trawl through historic records, generate “queries” to providers with suggested diagnoses and urge them to incorporate these into the chart months, and sometimes more than a year, after the encounters. In many instances, the diagnoses “had nothing to do with the patient visit in question, in violation of CMS requirements,” according to the Justice Department.
To reinforce the practice, Kaiser allegedly set “aggressive” physician‑ and facility‑specific goals for adding risk adjustment diagnoses, singled out underperforming doctors and facilities, and emphasised that failure to add codes cost money for Kaiser, its facilities and clinicians. Financial bonuses and incentives for physicians and facilities were allegedly tied to meeting these diagnosis‑capture targets.
The United States further alleged that Kaiser knew such addenda practices were “widespread and unlawful,” ignoring red flags from its own doctors and compliance auditors who raised concerns that false claims were being submitted to CMS.
The scale of the settlement and the rhetoric from senior officials underscore the government’s view that risk‑adjustment abuse in Medicare Advantage is a systemic threat. More than half of Medicare beneficiaries are now enrolled in Medicare Advantage plans, making the program central to the business model of many large insurers.
“More than half of our nation’s Medicare beneficiaries are enrolled in Medicare Advantage plans, and the government expects those who participate in the program to provide truthful and accurate information,” said Assistant Attorney General Brett A. Shumate, who heads the Justice Department’s Civil Division. “Today’s resolution sends the clear message that the United States holds healthcare providers and plans accountable when they knowingly submit or cause to be submitted false information to CMS to obtain inflated Medicare payments.”
U.S. Attorney Craig H. Missakian for the Northern District of California cast the case as part of a broader campaign against Medicare fraud. “Medicare Advantage is a vital program that must serve patients’ needs, not corporate profits,” he said. “Fraud on Medicare costs the public billions annually, so when a health plan knowingly submits false information to obtain higher payments, everyone — from beneficiaries to taxpayers — loses.”
Peter McNeilly, the U.S. Attorney for the District of Colorado, emphasised that the government “will hold health care plans accountable if they seek to game the system and pad their profits by submitting false information.”
The health department’s inspector general, Scott J. Lampert, called the deliberate inflation of diagnosis codes “a serious violation of public trust” that “undermines the integrity of the Medicare Advantage program.” The FBI’s Sanjay Virmani warned that “healthcare programs funded by the public are meant to support patients, not pad corporate bottom lines,” adding that the settlement “reflects the FBI’s continued commitment to holding accountable those who put profits over patients and abuse federal healthcare programs.”
For insurers, compliance and governance question marks
The case lays bare several practices that are likely to concern compliance officers and risk committees across the insurance sector:
• Extensive retrospective chart reviews designed primarily to increase revenue rather than improve care.
• Physician and facility incentives tied directly to risk‑adjustment coding output.
• Reliance on queries and addenda to append diagnoses long after the clinical encounter, rather than documenting conditions contemporaneously.
• Internal warnings from clinicians and compliance personnel that went unheeded.
For risk‑bearing organisations and their insurers, these elements will raise questions about the adequacy of internal controls, the independence and authority of compliance functions, and the extent to which performance incentives may conflict with regulatory obligations.
They also have implications for directors’ and officers’ liability. Prosecutors alleged that Kaiser “ignored numerous red flags and internal warnings,” including compliance audits and physician concerns, suggesting potential exposure not only for the entities themselves but for those overseeing their governance.
The settlement also illustrates the continued potency of the False Claims Act and its qui tam provisions in the healthcare and insurance arenas.
The Kaiser resolution resolves certain claims brought in whistleblower suits filed by former Kaiser employees Ronda Osinek and Dr. James M. Taylor in the Northern District of California. Under the Act, private parties can sue on the government’s behalf and receive a share of any recovery. The relators’ share in this case will be $95 million.
For insurers and health plans, the case is a reminder that employees involved in coding, compliance or clinical documentation can become key sources for enforcement agencies, and that internal dissent over aggressive risk‑adjustment tactics can quickly escalate into federal litigation.
The Justice Department has made clear that combating healthcare fraud remains a priority, describing the False Claims Act as “one of the most powerful tools” in that effort. The Kaiser settlement was the result of a coordinated investigation by the Civil Division’s Fraud Section, the U.S. Attorneys’ Offices in Northern California and Colorado, the Department of Health and Human Services’ Office of Inspector General and Office of Audit Services, and the FBI.
For the broader insurance industry, particularly carriers heavily invested in Medicare Advantage, the Kaiser case is likely to sharpen regulatory and investor scrutiny of risk‑adjustment practices.
The government’s theory of liability focuses not on whether diagnoses were ever present in a patient’s history, but whether they were properly documented and clinically relevant to specific encounters, as required by CMS. That distinction could put pressure on business models that rely heavily on retrospective chart reviews and home assessments that are loosely connected to ongoing care.
Insurers may now face:
• Increased audit and enforcement risk around diagnosis coding and risk‑adjustment analytics.
• Pressure to decouple clinician incentives from coding intensity, or at least to demonstrate robust safeguards against upcoding.
• Heightened diligence around third‑party vendors engaged in chart review and data mining.
• Stronger expectations from regulators and rating agencies that boards actively oversee Medicare Advantage compliance risk.
As with many civil False Claims Act settlements, Kaiser’s agreement does not include an admission of wrongdoing. The Justice Department stressed that “the claims resolved by the settlement are allegations only and there has been no determination of liability.”
Even so, a $556 million payment — accompanied by pointed public statements from senior law enforcement officials — will reverberate across an industry that has bet heavily on the growth and profitability of Medicare Advantage.
For insurers and reinsurers, the message is that risk‑adjustment revenue is now firmly in the enforcement spotlight. Coding practices once seen as a technical matter are being treated as a potential source of fraud, with consequences that extend beyond individual cases to the perceived integrity of the program itself.
